20
Fariba Willison Endogynaecology Flinders University Ashford Hospital PLATELET RICH PLASMA AND V2LR LASER THERAPY A New Approach to Managing Atrophic Vaginitis

A New Approach to Managing Atrophic Vaginitis. Decrease in Oestrogen after menopause Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Embed Size (px)

Citation preview

Page 1: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Fariba WillisonEndogynaecology

Flinders UniversityAshford Hospital

PLATELET RICH PLASMA AND

V2LR LASER THERAPY A New Approach to Managing Atrophic Vaginitis

Page 2: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Atrophic Vaginitis

Decrease in Oestrogen after menopause

Up to 40% of postmenopausal women suffer from Atrophic Vaginitis1

Decreased quality of life and direct impact on women’s sex life

- Vaginal dryness, painful sex, low libido, sluggish orgasm, urinary problems, vaginal infection

Page 3: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Atrophic Vaginitis

Decrease in oestrogen levels › Less Connective Tissue› Less capacity to retain water› Increased risk of fissuring &ulceration3

Decrease in glycogen in vagina tissue› Change in vaginal flora› Change in vagina pH› Increased risk of UTI& thrush

Page 4: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Atrophic Vaginitis

Normal Pap Smear• Abundant

Cytoplasm• Low Nuclear

Cytoplasmic Ratio

Atrophic Vaginitis Pap Smear• Enlarged Nuclei• Inflammatory Exudate• Amorphous

Basophillic Structurs (Blue Bulbs)

• Loss of Gylcogen in the Squamous Cells

Page 5: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Vaginal Wall 2-3 mm

1)Tunica mucosa(lining of the vagina) Epithelium regeneration 30 days, no glands Lamina Propria: vessels &elastic fiber

transudate

2)Tunica muscularis vaginal distention- Sex to birth. 3)Tunica adventitia

Low Magnification Vaginal Mucosa Medium Magnification Vaginal Mucosa

Page 6: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Vaginal MucosaTunica mucosa – epithelium & lamina

propria› Rich in collagen, Fibroblasts, & elastic

fibers› Proteoglycans retain large amount of

water

› The surgical stand point for vaginal repair(endopelvic facia)

Low Magnification Vaginal Mucosa Medium Magnification Vaginal Mucosa

Page 7: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Current Management

Oestrogen Replacement4

› Systemic or Local› Can reverse or prevent symptoms

Moisturizers and Lubricants› Can be independently or with oestrogen

replacement therapy Sexual Activity- 3 times per week

Page 8: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Current Management Drawbacks

Oestrogen Replacement› 10-25% of women do not respond5

› Some women will never fully respond› Small increase risk of endometrial ca› ? Oestrogen therapy in ER+ Breast cancer

Moisturizers and Lubricants› Short term benefit

Sexual Activity› No firm understanding of mechanism

Page 9: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Non-Surgical, Non-Hormonal Options

Platelet Rich Plasma Therapy - 27 gage needle and vaginal gel V2 LR Laser Therapy - using a vaginal probe

Page 10: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Platelet Rich Plasma

High concentration of platelets› Increased release of growth factors from

platelets› Promotes regeneration of connective tissue › Suggested applications in Dentistry,

Maxillofacial Surgery, Plastic Surgery, and Orthopaedic Surgery 6, 7, 8

Page 11: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis
Page 12: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

What is a Laser?

LASER - Light Amplification by Stimulated Emission of Radiation› An intense beam of light› Highly directional› A single wavelength or colour

Page 13: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

How does it work?

Pump some energy into it – electrically or with light› The material naturally emits light (of a characteristic colour)› Feedback (between the mirrors) build the intensity› Light ‘leaks’ out a partially reflecting mirror

Laser materialMirrorMirror

Energy in

excited

Light Laser beam

Page 14: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Interaction with the body

Pulsed lasers deliver a lot of energy in a very short time

Choice of laser determines the type of interaction

The CO2 Laser is ideal for skin resurfacing › Ablates away surface epidermal layers› Controlled dermal heating stimulates collagen tightening› Structured pulse pattern optimizes treatment efficacy

Page 15: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

CO2 Laser Therapy

Can be done in a clinic setting Works to restore vaginal mucosa to

pre-menopausal structure› Increases fibroblast activity› Promotes of Collagen synthesis› Increases H2O content resulting in

rehydration

Page 16: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Our pilot Study

Limited studies in Gynaecology to assess potential applications

Pilot study

› Women with painful intercourse due to severe atrophic vaginitis, recurrent thrush and scarring of the perineum 18 PRP 20 Laser 4 both PRP and Laser

Page 17: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Our Pilot study

Response to therapy based on:

› Symptom response of patients QOL and PISQ 12 questionnaires

› Colposcopic Changes/Biopsie Pre and Post treatment of vaginal mucosa

Page 18: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

Our Pilot study

Patients underwent 2-3 therapy sessions every 4 -6 weeks

Follow up with questionnaires at 1- 3 months( 85% improvement in PRP, 93% in Laser group and 100% in PRP and Laser

(4 women only) Post Therapy biopsy at 12 month follow

up will be performed Limitation of pilot study and need for

RCT

Page 19: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

FBW RCT study

Inclusion Criteria› Women with Atrophic Vaginitis

and breast Ca unable to use local HRT not responding to local HRT

› Women with recurrent thrush+ vaginismus› Women with vaginal dryness & irritation› Women with perineal scarring post delivery› Vaginal laxity

Exclusion Criteria› Acute bacterial Infections, active cancer, blood

disorders, anti-platelet medication, systematic auto-immune disorder

Page 20: A New Approach to Managing Atrophic Vaginitis.  Decrease in Oestrogen after menopause  Up to 40% of postmenopausal women suffer from Atrophic Vaginitis

References1. Greendale  GA, Judd  HL.  The menopause: health implications and clinical management.  J Am Geriatr Soc.  1993;41:426–362. Pandit  L, Ouslander  JG.  Postmenopausal vaginal atrophy and atrophic vaginitis.  Am J Med Sci.  1997;314:228–31.3. Rigg  LA.  Estrogen replacement therapy for atrophic vaginitis.  Int J Fertil.  1986;31:29–34.4. Handa  VL, Bachus  KE, Johnston  WW, Robboy  SJ, Hammond  CB.  Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium.  Obstet Gynecol.  1994;84:215–8.5. Smith  RN, Studd  JW.  Recent advances in hormone replacement therapy.  Br J Hosp Med.  1993;49:799–808.6. Robert E Marx, DDS, a, Eric R Carlson, DMDb, Ralph M Eichstaedt, DDSc, Steven R Schimmele, DDSd, James E Strauss, DMDe, Karen R Georgefff (RN) Platelet-rich plasma: Growth factor enhancement for bone grafts, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology Vol 85, Issue 6, June 1998, 638-6467. Eppley, Barry L. M.D., D.M.D.; Pietrzak, William S. Ph.D.; Blanton, Matthew M.D., Platelet-Rich Plasma: A Review of Biology and Applications in Plastic Surgery, Plastic and Reconstructive Surgery. Nov 2006 Vol 118 Issue 6 147-159 8. Timothy E. Foster, MD†*, Brian L. Puskas, MD†, Bert R. Mandelbaum, MD‡, Michael B. Gerhardt, MD‡ and Scott A. Rodeo, MD

Platelet-Rich Plasma From Basic Science to Clinical Applications, The American Journal of

Sports Medicine Nov 2009 Vol 37 no 11 2259-2272